BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Serper M, Parikh ND, Thiele G, Ovchinsky N, Mehta S, Kuo A, Ho C, Kanwal F, Volk M, Asrani SK, Ghabril MS, Lake JR, Merriman RB, Morgan TR, Tapper EB. Patient-reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology 2022;76:251-74. [PMID: 34990516 DOI: 10.1002/hep.32313] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Holman A, Parikh N, Clauw DJ, Williams DA, Tapper EB. Contemporary management of pain in cirrhosis: Toward precision therapy for pain. Hepatology 2023;77:290-304. [PMID: 35665522 DOI: 10.1002/hep.32598] [Reference Citation Analysis]
2 Liu Y, Wu Q, Sun T, Huang J, Han G, Han H. DNAAF5 promotes hepatocellular carcinoma malignant progression by recruiting USP39 to improve PFKL protein stability. Front Oncol 2022;12:1032579. [DOI: 10.3389/fonc.2022.1032579] [Reference Citation Analysis]
3 Allaire M, Bruix J, Korenjak M, Manes S, Maravic Z, Reeves H, Salem R, Sangro B, Sherman M. What to do about Hepatocellular Carcinoma: Recommendations for Health Authorities: An International Liver Cancer Association Advocacy Document. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100578] [Reference Citation Analysis]
4 Kardashian A, Serper M, Terrault N, Nephew LD. Health disparities in chronic liver disease. Hepatology 2022. [PMID: 35993341 DOI: 10.1002/hep.32743] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zhou Y, Qiu J, Liu S, Wang P, Ma D, Zhang G, Cao Y, Hu L, Wang Z, Wu J, Jiang C. CFDP1 promotes hepatocellular carcinoma progression through activating NEDD4/PTEN/PI3K/AKT signaling pathway. Cancer Med 2023;12:425-44. [PMID: 35861040 DOI: 10.1002/cam4.4919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Chen T, Tam N, Mao Y, Sun C, Wang Z, Hou Y, Xia W, Yu J, Wu L. A multi-hit therapeutic nanoplatform for hepatocellular carcinoma: Dual stimuli-responsive drug release, dual-modal imaging, and in situ oxygen supply to enhance synergistic therapy. Materials Today Bio 2022. [DOI: 10.1016/j.mtbio.2022.100338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]